Effect of verapamil in intermittent claudication: A randomized, double- blind, placebo-controlled, cross-over study after individual dose-response assessment

Circulation

Volumn 95, Issue 2, 1997, Pages 411-414

  Bagger, Jens Peder ^a,b   Helligsoe, Per ^a   Randsbaek, Flemming ^a   Kimose, Hans Henrik ^a   Jensen, Bent Skov ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

calcium antagonists; claudication; vasodilation

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; PLACEBO; VERAPAMIL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART MUSCLE OXYGEN CONSUMPTION; HEART PALPITATION; HEMODYNAMICS; HUMAN; INTERMITTENT CLAUDICATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLOW RELEASE FORMULATION; VASODILATATION; VERTIGO; WALKING;

EID: 0031037093     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.2.411     Document Type: Article

References (15)

1. Cameron HA, Waller PC, Ramsay LE. Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinical trials, 1965-1985. Br J Clin Pharmacol. 1988; 26:569-576.
2. Coffmann JD, Mannick JA. Failure of vasodilator drugs in arteriosclerosis obliterans. Ann Intern Med. 1972;76:35-39.
3. Bergqvist D, Karacagil S. Femoral artery disease. Lancet. 1994; 343:773-778.
4. Bagger JP, Nielsen TT, Henningsen P. The effect of verapamil on myocardial exchange of free fatty acids, citrate, lactate and glucose in coronary artery disease. Eur Heart J. 1983;4:406-414.
5. Bagger JP, Mathar R, Paulsen PK, Gormsen J, Olsen KH. Verapamil induced increment of oxygen extraction in the arteriosclerotic limb. Cardiovasc Res. 1985;19:567-569.
6. Kimose HH, Bagger JP, Aagaard MT, Paulsen PK. Placebo-controlled double-blind study of the effect of verapamil in intermittent claudication. Angiology. 1990;41:595-598.
7. Thomassen AR, Bagger JP, Nielsen TT, Henningsen P. Dose-related haemodynamic effects of nicardipine during rest and exercise and variable anti-anginal effects in patients with chronic stable angina. Eur Heart J. 1987;8:271-276.
8. Deanfield J, Wright C, Fox K. Treatment of angina pectoris with nifedipine: importance of dose titration. Br Med J. 1983;286: 1467-1470.
9. Armitage P, Berry G. Statistical Methods in Medical Research. Oxford, England: Blackwell Scientific Publications; 1987:222-226.
10. Pepine CJ, Schang SJ, Bemiller CR. Effects of perhexiline on coronary hemodynamic and myocardial metabolic responses to tachycardia. Circulation. 1974;49:887-893.
11. Bagger JP. Effects of antianginal drugs on myocardial energy metabolism in coronary artery disease. Pharmacol Toxicol. 1990; 66(suppl IV):1-31.
12. Schrumpf JD, Sheps DS, Wolfson S, Aronson AL, Cohen LS. Altered hemoglobin-oxygen affinity with long-term propranolol therapy in patients with coronary artery disease. Am J Cardiol. 1977;40:76-82.
13. Waller DG, Nicholson HP, Roath S. The acute effects of nifedipine on red cell deformability in angina pectoris. Br J Clin Pharmacol. 1984;17:113-118.
14. Neely JR, Morgan HE. Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Ann Rev Physiol. 1974;36:413-459.
15. Petersen FB. The effect of varying walking speed when measuring the claudication distance on horizontal and sloping levels. Acta Chir Scand. 1967;133:627-630.